Indivior Pharmaceuticals, Inc. Common Stock
Here’s whether Indivior Pharmaceuticals, Inc. Common Stock (INDV) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+1.00% over 10 days); RSI 47 — healthy momentum range; strong 1-year return of +53.3%. Concerns: below the 50-day MA (medium-term momentum negative). Currently 13.9% off its 52-week high. Score: +4/7.
INDV is holding above its long-term 200-day MA ($35.41) but has slipped below the 50-day MA ($39.56), pointing to short-term weakness in an otherwise intact trend. An RSI of 47.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +53.3% compares to +20.5% for SPY (beat the market by 32.8%).